Acrivon Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Acrivon Therapeutics, Inc. (ACRV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.66 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 359.10K shares, a 76.05% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.30M shares, a 12.17% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 236.05K shares, a 154.64% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 13.70K shares, a 62.72% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.51M shares, a 68.25% increase from fiscal 2024.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.49M shares, a 400.66% increase from fiscal 2023.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 297.56K shares, a 88.17% decline from fiscal 2022.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.52M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 359.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 2.66M shares 10-Q · filed 2026-08-12 | 2.90M shares derived: sum of 3 quarters · filed 2026-08-12 | 2.91M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 2.30M shares 10-Q · filed 2026-05-13 | 2.54M shares derived: sum of 2 quarters · filed 2026-05-13 | 2.55M shares derived: sum of 3 quarters · filed 2026-05-13 | 2.76M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 236.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 249.75K shares derived: sum of 2 quarters · filed 2026-03-19 | 453.73K shares derived: sum of 3 quarters · filed 2026-03-19 | 2.51M shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 13.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 217.68K shares derived: sum of 2 quarters · filed 2025-11-13 | 2.27M shares 10-Q · filed 2025-11-13 | 2.36M shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 203.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 2.26M shares 10-Q · filed 2025-08-13 | 2.35M shares derived: sum of 3 quarters · filed 2025-08-13 | 2.39M shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 2.05M shares 10-Q · filed 2025-05-14 | 2.15M shares derived: sum of 2 quarters · filed 2025-05-14 | 2.18M shares derived: sum of 3 quarters · filed 2025-05-14 | 2.30M shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 92.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 129.45K shares derived: sum of 2 quarters · filed 2025-03-27 | 248.18K shares derived: sum of 3 quarters · filed 2025-03-27 | 1.49M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 36.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 155.47K shares derived: sum of 2 quarters · filed 2024-11-13 | 1.40M shares 10-Q · filed 2024-11-13 | 1.46M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 118.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 1.36M shares 10-Q · filed 2024-08-13 | 1.42M shares derived: sum of 3 quarters · filed 2024-08-13 | 1.55M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 1.24M shares 10-Q · filed 2024-05-14 | 1.30M shares derived: sum of 2 quarters · filed 2024-05-14 | 1.43M shares derived: sum of 3 quarters · filed 2024-05-14 | 1.50M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 61.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 187.77K shares derived: sum of 2 quarters · filed 2024-03-28 | 260.36K shares derived: sum of 3 quarters · filed 2024-03-28 | 297.56K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 126.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 199.19K shares derived: sum of 2 quarters · filed 2023-11-09 | 236.39K shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 72.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 109.79K shares 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | 37.20K shares 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | 2.52M shares 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |